Biotechnology

Recursion Pharmaceuticals

Recursion Pharmaceuticals released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 6.472 M (forecast USD 15.78 M), actual EPS USD -0.2219 (forecast USD -0.255)

Recursion Pharmaceuticals to Release FY2026 Q1 Earnings on May 6, Pre-Market EST; Forecast Revenue USD 17.46 M, EPS USD -0.2556

Recursion Pharmaceuticals released FY2025 Q4 earnings on February 25 Pre-Market (EST), actual revenue USD 35.54 M (forecast USD 24.56 M), actual EPS USD -0.2071 (forecast USD -0.285)

Recursion Pharmaceuticals released FY2025 Annual Earnings on February 25 Pre-Market (EST), actual revenue USD 74.68 M (forecast USD 61.61 M), actual EPS USD -1.4409 (forecast USD -1.5853)

ARK Investment Increases Biotech Holdings and Reduces Tech Stocks

Recursion Pharmaceuticals to Release FY2025 Q4 Earnings on February 25, 2026 Pre-Market EST, Forecast Revenue USD 24.56 M, EPS USD -0.285

Christopher Gibson Sells Recursion Pharmaceuticals Inc. Stock

Six Analysts Give Recursion Pharmaceuticals a Hold Rating

Recursion Pharmaceuticals Director Sold Shares

Cathie Wood's ARK Investment Buys Recursion Pharmaceuticals Shares

Recursion Pharmaceuticals Inc.'s Chief R&D Commercial Officer Sells Shares

Recursion Pharmaceuticals CEO Plans to Sell 40,000 Shares

JPMorgan upgrades Recursion Pharmaceuticals rating

Recursion Pharmaceuticals Shares Show Initial Rebound, Undervalued and Advised for Exploration of Investment Opportunities

Recursion Pharma's Drug REC-4881 Shows Promising Results in Clinical Trials

Recursion Pharmaceuticals CEO Announces Sale of Common Stock

Blake Borgeson reports disposal of Recursion Pharmaceuticals common stock

Recursion Pharmaceuticals to Release New Data on REC-4881 for Familial Adenomatous Polyposis

Recursion Pharmaceuticals Issues Shares to Tempus AI

Recursion Pharmaceuticals Inc Executives Sell Stocks

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AXSM

RXRX

LABU

ARKG

SBIO

Three companies are set to disrupt the healthcare market by 2030: Tempus AI, Recursion Pharmaceuticals, and Axsome Therapeutics. Tempus AI focuses on precision medicine by aggregating clinical and genomic data to enhance treatment decisions, projecting significant revenue growth. Recursion Pharmaceuticals aims to revolutionize drug discovery through automation and machine learning, though it is still in the investment phase. Axsome Therapeutics targets central nervous system disorders with its fast-acting antidepressant, Auvelity, and is expanding its market reach, showing promising revenue growth despite high operating costs.

nasdaq

Axsome Therap

Tempus AI

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

iShares Global Healthcare

iShares Genomics Immunology and Healthcare ETF

VG Health

iShares US Healthcare Providers

VanEck Biotech ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares US Pharma

Tradr 2X Long TEM Daily ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

NVIDIA

Intel

Bayer AG

Bayer

ROCHE HOLDINGS AG

Roche

UBS Group AG

NVIDIA Corporation

Bayer Aktiengesellschaft

3 Stocks Poised to Disrupt the Healthcare Market by 2030

Recursion Pharmaceuticals is set to update on the FDA trial design for its drug REC-4881 for familial adenomatous polyposis (FAP) in late 2026. Despite potential upside from rare diseases, shares have fallen 3.85% to $3.30. Analyst Gil Blum maintains a Buy rating with a price target of $8, citing a 30% year-on-year decline in operating expenditure. The pivotal trial design update is expected to be a key value driver, focusing on patient populations and dose optimization, supported by AI-enabled clinical platforms.

benzinga_article

Proshares Ultra Nasdaq Biotech

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

Recursion Pharmaceuticals (NASDAQ: RXRX) emphasized its focus on AI-driven drug discovery during its Q1 earnings call. CEO Najat Khan highlighted early clinical proof-of-concept for REC-4881 in familial adenomatous polyposis, ongoing Phase 1 studies for REC-1245 and REC-4539, and a commitment to tighter financial discipline. The company is engaging with the FDA to define a registrational path for REC-4881 and reported promising safety data for REC-1245. REC-4539 has also entered Phase 1 trials, aiming to address challenges faced by previous LSD1 inhibitors.

Market Beat

Absci

Recursion Pharmaceuticals Q1 Earnings Call Highlights

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly earnings of ($0.22) EPS, surpassing estimates of ($0.30) by $0.08. The company had a revenue of $6.47 million, significantly below the expected $15.78 million, marking a 56.8% year-over-year decline. Despite a negative net margin of 863.37% and a negative return on equity of 63.98%, the firm maintains a strong cash position of $665 million, projected to fund operations into early 2028. Stock price rose 1.3% to $3.42, with mixed analyst ratings and a consensus target price of $9.20.

C3.AI

Spectral AI

Robo.ai

Nano Labs

Zensho Holdings Co., Ltd.

Financial Street

Charter Hall Long WALE REIT

Landbridge Co LLC

Chemours

New England Real Asso

Weis Markets

Carl Zeiss Meditec AG

NEUBERGER BERMAN REAL ES-W/I

JPMorgan Chase

Bank of America

SPECTRAL AI INC C/WTS 11/09/2028(TO PUR COM)

ROBO.AI INC. C/WTS 11/11/2027 (TO PUR COM)

Charter Hall Retail REIT

Charter Hall Group

Charter Hall Social Infrastructure REIT

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Quarterly Earnings Results

Earnings Watch

Recursion Pharmaceuticals | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 6.472 M

Recursion reported its first quarter financial results, highlighting significant progress in its clinical pipeline. Key updates include positive early clinical data for REC-1245, a well-tolerated RBM39 degrader, and strong efficacy signals for REC-4881, an allosteric MEK1/2 inhibitor. The company also dosed its first patient in the Phase 1 study of REC-4539, an LSD1 inhibitor. Recursion reiterated its operational cash burn guidance of under $390 million for 2026, supporting its financial runway into early 2028. An earnings call is scheduled for May 6, 2026, to discuss these developments further.

Fidelity

Recursion Reports First Quarter Financial Results and Provides Business Update